$STOK

Stoke Therapeutics, Inc.

Stoke Therapeutics is a late-stage clinical company developing RNA-based antisense oligonucleotide medicines intended to increase protein expression and address the underlying causes of severe diseases. Its proprietary TANGO platform is designed to alter RNA splicing and increase protein production from a healthy gene copy. Stoke’s initial focus is on genetic diseases of the central nervous system and eye. Its lead candidate, zorevunersen, is in a global Phase 3 study for Dravet syndrome. STK-002 is being evaluated in a Phase 1 study for autosomal dominant optic atrophy, and Stoke is advancing preclinical programs in other disease areas. The company aims to earn money through development and commercialization of its medicines, including a collaboration with Biogen covering zorevunersen outside the U.S., Canada and Mexico. Stoke Therapeutics is headquartered in Bedford, Massachusetts.

AlphAI earnings readThird Quarter 2026 · OCT 29Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business UpdatesVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

2
0
0
—
$190K
Ticho Barry
100%
See all $STOK insider activity →
Low

Stoke Therapeutics: 3 Key Takeaways for Long-Term Investors

Stoke Therapeutics (STOK) reported FDA alignment on Zorevunersen's approval pathway, with a composite endpoint for cognitive and behavioral assessments. The EMPEROR Phase III trial has 100% patient retention. The company plans to focus on 50 specialized centers for launch, treating half of U.S. Dravet syndrome patients. Stoke has $358.8M in cash, funding operations into 2028. STK-002 is in Phase I trials for autosomal dominant optic atrophy.

ULA’s Latest Launch Failure Spells Trouble for Space Force

United Launch Alliance's (ULA) Vulcan Centaur rocket failed during a Nov. 15 launch, destroying 40 Amazon satellites and tightening Space Force launch capacity. The issue was attributed to inadequate fuel supply to the BE-4 engines, built by Blue Origin. ULA faces further investigation, while SpaceX's successful Starship test cements its dominance.

Goldman Sachs lowers Stoke Therapeutics price target on expenses

Goldman Sachs reduced Stoke Therapeutics' (STOK) price target to $43 from $44, maintaining a Buy rating. The company reported Q3 2026 operating expenses of $88.6M, higher than estimates. Revenue was $11.25M, exceeding expectations. The Phase 3 EMPEROR trial for zorevunersen is on track for a 2027 readout. STOK trades at $26.35 with a Strong Buy consensus.

STOK sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning STOK (Stoke Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.

Recent STOK coverage spans technology, earnings and financial news.

In the last 30 days, STOK insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($190K). The most active reporter was Ticho Barry, CHIEF MEDICAL OFFICER, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving STOK

AlphAI scores every news story that mentions STOK with an AI model for sentiment and relevance, and aggregates insider trades from Stoke Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $STOK

Score

Stoke Therapeutics: 3 Key Takeaways for Long-Term Investors

Stoke Therapeutics (STOK) reported FDA alignment on Zorevunersen's approval pathway, with a composite endpoint for cognitive and behavioral assessments. The EMPEROR Phase III trial has 100% patient retention. The company plans to focus on 50 specialized centers for launch, treating half of U.S. Dravet syndrome patients. Stoke has $358.8M in cash, funding operations into 2028. STK-002 is in Phase I trials for autosomal dominant optic atrophy.

ULA’s Latest Launch Failure Spells Trouble for Space Force

United Launch Alliance's (ULA) Vulcan Centaur rocket failed during a Nov. 15 launch, destroying 40 Amazon satellites and tightening Space Force launch capacity. The issue was attributed to inadequate fuel supply to the BE-4 engines, built by Blue Origin. ULA faces further investigation, while SpaceX's successful Starship test cements its dominance.

Stoke Q3 2026 slides: EMPEROR trial advances with zero dropouts

Stoke Therapeutics (STOK) reported Q3 2026 progress, highlighting zero dropouts in its EMPEROR Phase 3 trial for zorevunersen in Dravet syndrome. The company beat revenue estimates but reported a wider-than-expected loss. Stoke has $358.8M in cash, enough to fund operations into early 2028. The trial enrolled 162 patients, exceeding the target, with strong patient retention and statistical significance in endpoints. The FDA has accepted the study's multicomponent approach for regulatory filing.

$STOKMedEarnings

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics, Inc. (STOK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX 99.1 Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates –Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome: ~110 patients through Week 28 primary endpoint, ~20 patients through Week 52 and all co

$STOKMedAI 8/10

About 110 patients reached the seizure-measurement point in a Dravet drug trial

Stoke Therapeutics reported progress in its Phase 3 EMPEROR study for zorevunersen, an investigational drug for Dravet syndrome, with 110 patients reaching the Week 28 primary endpoint. The company plans to submit data to the FDA in the first half of 2027 and complete the NDA submission in the second half. Additionally, the Phase 1 OSPREY study for STK-002, targeting ADOA, is ongoing with initial data expected in H1 2027.

Stoke Therapeutics earnings: Investors brace for revenue test

Stoke Therapeutics (STOK) reports Q3 earnings, with analysts expecting a $0.93 loss per share on $8.21M revenue, down 12% sequentially. The company is developing RNA medicines, with key updates on zorevunersen for Dravet syndrome and STK-002 for optic atrophy. All 14 analysts rate it a Strong Buy with a $46.46 target, implying 75.9% upside. Investors will focus on revenue trends and clinical progress.

Stoke Therapeutics presents data on ADOA treatment STK-002

Stoke Therapeutics (STOK) presented data on STK-002, an experimental treatment for Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology 2026 Annual Meeting. The Phase 1 OSPREY study completed dosing in the first two cohorts, with initial safety and efficacy data expected in 2027. STK-002 targets the OPA1 gene, which causes 65-90% of ADOA cases. The study aims to assess safety, tolerability, and visual function improvements.

$STOKMedAI 8/10

A Dravet medicine trial will measure changes in four areas of thinking and behavior

Stoke Therapeutics (STOK) completed a meeting with the FDA to align on the planned U.S. NDA for zorevunersen, an investigational treatment for Dravet syndrome. The Phase 3 EMPEROR study will assess changes in cognition and behavior using four Vineland-3 subdomains. Data submissions are expected in the first half of 2027, with a Phase 3 readout anticipated in Q3 2027. The company plans to complete the NDA submission in the second half of 2027.

Related tickers